PMCB logo

PharmaCyte Biotech, Inc. Stock Price

NasdaqCM:PMCB Community·US$7.2m Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 1 Fair Values set on narratives written by author

PMCB Share Price Performance

US$0.71
-0.84 (-54.19%)
US$0.71
-0.84 (-54.19%)
Price US$0.71

PMCB Community Narratives

There are no narratives available yet.

Trending Discussion

Updated Narratives

No recently updated narratives available.

Snowflake Analysis

Adequate balance sheet with slight risk.

4 Risks
0 Rewards

PharmaCyte Biotech, Inc. Key Details

US$0

Revenue

US$0

Cost of Revenue

US$0

Gross Profit

US$7.6m

Other Expenses

-US$7.6m

Earnings

Last Reported Earnings
Oct 31, 2025
Next Reporting Earnings
n/a
-0.75
0%
0%
0%
View Full Analysis

About PMCB

Founded
1996
Employees
2
CEO
Joshua Silverman
WebsiteView website
pharmacyte.com

PharmaCyte Biotech, Inc., a biotechnology company, focused on developing and preparing to commercialize cellular therapies for cancer using live cell encapsulation technology in the United States. The company’s cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. It also develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; license agreements with SG Austria Pte. Ltd.; and Austrianova Singapore Pte. Ltd. to use the Cell-in-the-Box technology for cancer treatment. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.

Recent PMCB News & Updates

Recent updates

No updates